Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd

Bullboard Posts

Comment by somguyincanadaon Oct 01, 2011 9:38am

359 Views

Post# 19107210

RE: Marban Project is Looking Good

I thought Aurizon was committed for 3 years. The following suggests that they can pull out??? September 30th has come and gone. Is Aurizon still in? Any one know?Excerpt from report:Aurizon has a September 30th deadline to decide if it will continue to work towards completing the option agreement which involve spending $20 million on exploration over three years, completing an updated NI 43-101 resource estimate andmaking a payment based on the total measured and indicated plus inferred gold resources. We had originally anticipated a formal announcement that Aurizon would continue with the joint venture on or prior to September 30th deadline but itappears that will not be the case.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity